Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management

The disease burden of AF is greater in Asia-Pacific than other areas of the world. Direct oral anticoagulants (DOACs) have emerged as effective alternatives to vitamin K antagonists (VKA) for preventing thromboembolic events in patients with AF. The Asian Pacific Society of Cardiology developed this...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Daniel TT Chong, Felicita Andreotti, Peter Verhamme, Jamshed J Dalal, Noppacharn Uaprasert, Chun-Chieh Wang, Young Keun On, Yi-Heng Li, Jun Jiang, Koji Hasegawa, Khalid Almuti, Rong Bai, Sidney TH Lo, Rungroj Krittayaphong, Lai Heng Lee, David KL Quek, Sofian Johar, Swee-Chong Seow, Christopher J Hammett, Jack WC Tan
Formato: article
Lenguaje:EN
Publicado: Radcliffe Medical Media 2021
Materias:
Acceso en línea:https://doaj.org/article/49c5064400184fe5a7cde8efc907810e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The disease burden of AF is greater in Asia-Pacific than other areas of the world. Direct oral anticoagulants (DOACs) have emerged as effective alternatives to vitamin K antagonists (VKA) for preventing thromboembolic events in patients with AF. The Asian Pacific Society of Cardiology developed this consensus statement to guide physicians in the management of AF in Asian populations. Statements were developed by an expert consensus panel who reviewed the available data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting 17 statements provide guidance on the assessment of stroke risk of AF patients in the region, the appropriate use of DOACs in these patients, as well as the concomitant use of DOACs and antiplatelets, and the transition to DOACs from VKAs and vice versa. The periprocedural management of patients on DOAC therapy and the management of patients with bleeding while on DOACs are also discussed.